Back to results
US 12,708,607 B2Granted
Thromboxane receptor antagonist formulations
AssigneeAtxa Therapeutics Limited
InventorsB. Therese Kinsella, Helen Reid, Eamon Mulvaney
Life of this patent
Estimating the term…
Abstract
The present invention provides formulations that enhances bioavailability of thromboxane receptor antagonists allowing them to bind to the thromboxane A2 receptors in subjects suffering from disease indications in which the prostanoid thromboxane A2, and incidental thromboxane A2 receptor ligands, are implicated. The formulations comprise a solid dispersion comprising a benzenesulfonyl urea and a polymer that are suitable for administration through oral or other routes of delivery.
Claims9
A formulation comprising:
- a spray dried amorphous solid dispersion comprising:
- a drug comprising a substituted benzenesulfonyl urea of formula (IV)
- a vinylpyrrolidone-vinyl acetate copolymer, wherein a ratio of the substituted benzenesulfonyl urea to the vinylpyrrolidone-vinyl acetate copolymer is between 1:4 and 1:8.
Dependencies are inferred from the claim text.